LDOSBy Calypso Research8 min read

Leidos Holdings (LDOS) Q4 2025 Earnings Analysis

FYI: Leidos Sees $4.2B in CapEx-tional Challenges

Key Takeaways

Leidos Holdings (LDOS) reported Q4 2025 earnings with revenue of $4.2B, representing a -3.6% year-over-year change. The stock moved -8.4% on earnings day.

The bull case: Leidos’ focused North Star 2030 strategy, elevated but targeted CapEx, and strengthening defense-tech and health franchises drive accelerating growth, sustained double-digit EPS expansion, and further margin upside beyond 2026.

The bear case: Award timing risk, VA health recompete pressure, elevated CapEx with uncertain long-term run-rate, and potential AI- and outcome-based pricing headwinds could cap growth, compress margins from 2025 peaks, and limit capital returns to shareholders.

Financial Highlights

  • Revenue: $4.2B (-3.6% YoY)
  • Gross Profit: $673M (16.0% margin, +0.1% YoY)
  • Operating Income: $471M (11.2% margin, +1.6% YoY)
  • Net Income: $335M
  • TTM Revenue: $17.2B

Stock Performance

  • Earnings Day Move: -8.4%
  • Year-to-Date: -6.3%
  • 1-Year Return: +34.1%
  • vs. S&P 500 (since earnings): -17.7%
  • vs. Nasdaq (since earnings): -14.9%

View live LDOS data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Leidos Holdings's Q4 2025 earnings call:

Scale, Focus, and Returns of Elevated CapEx and Co‑Investment (Defense, FAA, Health)

Sentiment: Positive

"we are negotiating several framework agreements with the Department of War when it comes to co-investment opportunities for exciting franchise programs for Leidos going forward. But that is not where all of that CapEx and all of that investment is going. We are investing in all the growth pillars now that we have a sound key strategy to grow this company into the future." — Thomas A. Bell
"the items we are investing in this year are to scale up, for the most part, scale up capabilities that are in programs that we are executing on or see clear line of sight demand for expansion... but I do not I do not think that you would say the $350,000,000 of CapEx is the new normal... it was situation dependent, we have the capacity to do that if if the business case is there, but not necessarily what we see on enduring basis." — Christopher R. Cage

Growth Algorithm: 2026 Guide vs. Back‑Half Acceleration and Book‑to‑Bill Sustainability

Sentiment: Positive

"lower growth in the first half of the year, acceleration in the back half of the year, some of the things that we have been talking about over the last several quarters we have not seen you know, any significant money yet put towards some of the Golden Dome initiatives the FAA modernization, etcetera, those are catalysts that can help propel the second half." — Christopher R. Cage
"we saw about $7,000,000,000 in awards slip from Q4 into this quarter. And our we have now $20,000,000,000 of pending awards and a $49,000,000,000 of backlog. So we have a high proposal activity... we expect those awards to start coming in, and that will feed growth through the end of the year as those programs get on to execution." — Thomas A. Bell

Health Segment Durability and VA Medical Disability Exams (MDE) Recompete Risk

Sentiment: Positive

"we have no intention to to seed this market space despite, as Chris mentioned in his commentary, the entry of the fourth fender and the possibility of a work share reallocation. That being said, we see volume continuing to go up... we think we have everything to compete and win to continue to serve our customers best and the this nation's veterans best." — Thomas A. Bell
"if you go back to my prepared remarks, you know, we kinda gave a horizon view in looking at Health beyond 2026, robust profitability above 20%. That certainly contemplates how we envision this recompete unfolding over time... This is an area that we can sustain very attractive returns in, and we are excited to demonstrate that." — Christopher R. Cage

Capital Allocation Priorities Post‑Entrust: M&A vs. Buybacks vs. Balance Sheet

Sentiment: Mixed

"now with our, North Star 2030 strategy, in hand and we have been firmly in strategy execution mode... inorganic and organic investments will be the lion's share how we deploy our capital in the near term. That being said, we will continue to our our dividend program, and we will look opportunistically for other shareholder friendly deployments of capital as the as the need arises." — Thomas A. Bell
"to get to your specific question on the repos, we have not baked any into the guide that we gave you for this year. I mean, you can see that with interest coming online, there is a lot of capital going to that. But we have more capacity, and the priorities are what Tom laid out. And we will monitor things as the year unfolds." — Christopher R. Cage

Margin Sustainability and Upside Beyond Mid‑13% EBITDA in 2026

Sentiment: Positive

"we dropped some breadcrumbs for you there, Gavin, to see that the best is yet to come on margins in our newly formed Homeland segment and certainly with additional upside in Defense... the expectation is, yeah, we are not done with margins, but consolidate the gains we have made reprioritize. Fund the critical investments for growth, and then deliver exceptional results on that in 2027 and beyond." — Christopher R. Cage
"do not negate the effects of our transformation office. We are very bullish about that being able to help Leidos become more efficient. And as a result, obviously, there could be some margin uplift there as our overheads come down. And as the year goes on, as we bring in Entrust, we expect that to be margin accretive." — Thomas A. Bell

Bull Case

Leidos’ focused North Star 2030 strategy, elevated but targeted CapEx, and strengthening defense-tech and health franchises drive accelerating growth, sustained double-digit EPS expansion, and further margin upside beyond 2026.

Bear Case

Award timing risk, VA health recompete pressure, elevated CapEx with uncertain long-term run-rate, and potential AI- and outcome-based pricing headwinds could cap growth, compress margins from 2025 peaks, and limit capital returns to shareholders.

Looking Ahead

With revenue declining -3.6% year-over-year, investors will be watching for signs of a turnaround at Leidos Holdings, particularly around scale, Focus, and Returns of Elevated CapEx and Co‑Investment (Defense, FAA, Health). With operating margins at 11.2%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Leidos Holdings's revenue in Q4 2025?

Leidos Holdings reported Q4 2025 revenue of $4.2B, representing a -3.6% year-over-year change.

Did Leidos Holdings beat earnings expectations in Q4 2025?

The stock declined -8.4% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Leidos’ focused North Star 2030 strategy, elevated but targeted CapEx, and strengthening defense-tech and health franchises drive accelerating growth, sustained double-digit EPS expansion, and further margin upside beyond 2026.

What is the bull case for LDOS stock?

The bull case for LDOS centers on: Leidos’ focused North Star 2030 strategy, elevated but targeted CapEx, and strengthening defense-tech and health franchises drive accelerating growth, sustained double-digit EPS expansion, and further margin upside beyond 2026.

What is the bear case for LDOS stock?

The bear case for LDOS centers on: Award timing risk, VA health recompete pressure, elevated CapEx with uncertain long-term run-rate, and potential AI- and outcome-based pricing headwinds could cap growth, compress margins from 2025 peaks, and limit capital returns to shareholders.

How has LDOS stock performed since its Q4 2025 earnings?

LDOS moved -8.4% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +17.7% since earnings. Year-to-date, the stock has returned -6.3%.

Browse all 400+ earnings reports →

Learn More

Analyze LDOS in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Leidos Holdings and 400+ other stocks, explore the full platform.

Open LDOS on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.